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ABSTRACT 
Background  
Occipital nerve stimulation is a potential treatment option for medically intractable short-
lasting unilateral neuralgiform headache attacks.  We present long-term outcomes in 31 
patients with short-lasting unilateral neuralgiform headache attacks treated with occipital 
nerve stimulation in an uncontrolled open-label prospective study. 
Methods  
Thirty-one patients with intractable short-lasting unilateral neuralgiform headache attacks 
were treated with bilateral occipital nerve stimulation from 2007 to 2015. Data on attack 
characteristics, quality of life, disability and adverse events were collected. Primary endpoint 
was change in mean daily attack frequency at final follow-up.   
Results 
At a mean follow-up of 44.9 months (range 13-89) there was a 69% improvement in attack 
frequency with a response rate (defined as at least a 50% improvement in daily attack 
frequency) of 77%.  Attack severity reduced by 4.7 points on the verbal rating scale and 
attack duration by a mean of 64%.  Improvements were seen in headache-related disability 
and depression.  Adverse event rates were favorable with no electrode migration or erosion 
reported. 
Conclusion 
Occipital nerve stimulation appears to offer a safe and efficacious treatment for refractory 
short-lasting unilateral neuralgiform headache attacks with significant improvements 
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sustained in the long-term.  The procedure has a low adverse event rate when conducted in 
highly specialised units.  
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INTRODUCTION 
Short-lasting unilateral neuralgiform headache attacks (SUNHA) are a rare form of primary 
headache syndrome characterized by attacks of unilateral pain occurring in the trigeminal 
distribution.  The pain is of moderate to severe intensity and is accompanied by at least one 
cranial autonomic symptom or sign, ipsilateral to the pain 1.  Attacks can last 1-600 seconds 
with attack frequency ranging between 1 and over 200 a day 1, 2.  The International 
Classification of Headache Disorders (ICHD-3beta) describes two subsets of the syndrome 
defined by the presence of ipsilateral tearing and conjunctival injection: short-lasting 
unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) 
(where both lacrimation and conjunctival injection are present) and short-lasting unilateral 
neuralgiform headache attacks with autonomic features (SUNA) (where only one of or neither 
of lacrimation or conjunctival injection are present) 1.  The chronic form of SUNHA is 
defined as attacks occurring for over one year with remission periods of less than one month.  
Seventy percent of patients suffer the chronic variant 2. 
First line treatment for the condition is lamotrigine but other drugs such as topiramate, 
oxcarbazepine and gabapentin have been reported to be effective3-7.  Temporary response to 
lidocaine infusions and greater occipital nerve blocks have also been reported 8-10.  Short-
lasting unilateral neuralgiform headache attacks can be difficult to treat medically and some 
patients prove intractable to treatment.  In the past, such patients have been subject to 
destructive procedures of the trigeminal nerve with poor long-term outcomes 11.  However, 
recent meta-analysis suggests that microvascular decompression of the ipsilateral trigeminal 
nerve in selected patients with intractable SUNHA and neurovascular contact may be useful 
12.  Long-term outcome data from this procedure is awaited. 
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Peripheral (occipital nerve stimulation) and central (ventral tegmental area deep brain 
stimulation) neurostimulation techniques have been carried out with some success for the 
syndrome. Our group have recently reported a cohort of 11 patients who have undergone deep 
brain stimulation for SUNHA with a median improvement in daily attack frequency of 78% 
with an at least 50% reduction in attack frequency seen in nine patients13 .  Deep brain 
stimulation is, however, highly invasive and associated with a small risk of fatal intracerebral 
hemorrhage 14. Occipital nerve stimulation (ONS) appears potentially useful for chronic 
migraine based on a small number of randomized trials and for chronic cluster headache 
based on a number of open-label series 15-22.  Safety profile has been dominated by high lead 
migration and infection rates.  The experience of ONS in the treatment of SUNHA is limited 
to a single series of nine patients 23.   In this prospective open-label series we report the long-
term follow-up of 31 medically intractable chronic SUNHA patients treated with ONS who 
had tried numerous other treatment options available to them within the UK’s National Health 
Service. 
 
METHODS 
Patients 
Under the supervision of our institution’s Clinical Effectiveness Supervisory Committee 
(CESG) with arrangements for clinical governance, consent and audit, we offered ONS to 
medically intractable SUNHA. The procedure was provided on the basis of a “humanitarian 
intervention”. In addition, ethic board approval for data collection and publication was 
granted by Northwick Park Hospital Research Ethics Committee, Hampstead, London, UK.  
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Patients were reviewed in a multidisciplinary clinic and were implanted over a period from 
2007 to 2013.  All patients fulfilled International Classification of Headache Disorders 2nd 
edition at time of diagnosis 24.  Although four patients had longer duration attacks (between 
15-45 minutes) than in ICHD criteria this has been described in other large clinical series and 
all had had some attacks less than 10 minutes during the course of the syndrome 2.  Patients 
with longer lasting attacks underwent Indometacin trials (oral or intramuscular) to rule out 
indometacin-sensitive headaches 25.  Unlike chronic cluster headache or migraine, 
intractability is not defined for SUNHA and so local criteria were devised.  Patients were 
considered for ONS if they had had disabling chronic SUNHA for at least two years and had 
failed adequate trials of lamotrigine, topiramate, gabapentin, pregabalin and one of either 
carbamazepine or oxcarbazepine 23.  Agents were selected on the basis of reported efficacy 
and local experience 2, 26.  Failed trials were defined as a lack of response, intolerable side 
effects or contraindications to use of medication.  Microvascular decompression was not 
available to the patient group during the study period.  Given the lack of evidence to support 
its use as a predictor of ONS outcome, response to greater occipital nerve block was not 
considered in patient selection 27. 
 
Surgical Procedure 
Bilateral ONS electrodes, leads and an implantable pulse generator (IPG) were implanted in all 
patients (Table 1).  Systems from both Medtronic (n=26) and St Jude Medical (n=5) were utilized 
with octad electrodes used in all.  The patient was placed into the lateral position and a midline 
posterior cervical incision made.  Initially, the insertion point of the electrodes was the spinous 
process of C1, passing superior and laterally, using a curved Tuohy needle and an image intensifier 
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to aid positioning.  This method evolved over time so that implantation level was aimed at the 
greater occipital nerve as it emerged superior to the nuchal line.  In this amended technique, the 
electrode was passed using a blunt plastic tube to limit the risks of the electrode tip being tunneled 
too close to the skin.  The evolution of surgical technique occurred in response to adverse events 
such as recruitment of neck muscles during stimulation or erosion of the electrode tip through the 
scalp.  Given that both techniques target the same nerve it is felt unlikely that the implant technique 
would directly account for changes in efficacy.  Electrodes were looped and anchored to cervical 
fascia and then tunneled to a lateral cervical or infraclavicular skin crease intermediate incision.  An 
infraclavicular or abdominal incision was made (according to patient preference) and a pocket 
formed into which the IPG was placed.  Electrodes were tunneled to the intermediate incision site 
where a pair of extension leads were connected.  Silicone sheaths were used to protect lead 
connections.  Topical gentamicin was introduced around the pocket prior to closure.  Our unit did 
not employ trial stimulation as it was felt that the current evidence to support its use is outweighed 
by the risks of extra surgical procedures. 
Patients were provided with remote controls allowing them to adjust their stimulation 
amplitude but were asked to use continuous stimulation where possible.  Polarity of the 
electrodes was adjusted during follow up visits to ensure comfortable bilateral paresthesia in 
the occipital region.  Stimulation settings and changes were recorded at each visit.  
Medications were changed as needed at the discretion of the headache specialist.   
 
Data Collection 
Primary outcome measure was the change in mean daily attack frequency.  Secondary 
measures included: the clinical response to ONS (defined as a more than 50% reduction in 
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attack frequency), changes in attack severity and duration, headache specific disability scores, 
quality of life scores and affect scores. 
Outcome data was collected and recorded prospectively.  Prospective headache diaries were 
kept for one month prior to implant and then two weeks prior to each follow-up visit.  All 
patients were shown how to keep a paper diary recording the duration and pain intensity of 
their attacks and asked to record all daily attacks.   Patients were seen at three-monthly 
intervals post-implant for one year and at least six to twelve monthly thereafter depending on 
clinical condition.  Data was collected on demographics, diagnosis, treatments, attack 
frequency, severity and duration, headache disability scores, quality of life scales, affective 
scores, ONS settings and adverse events.  Although specific tools for measuring the 
associated disability of SUNHA have yet to be validated, Migraine Disability Assessment 
Scores (MIDAS) and Headache Impact Test-6 (HIT-6) scores were conducted.  These scores 
have been used extensively in the assessment of primary headache disorders and previously 
used to monitor response of trigeminal autonomic cephalalgias, including SUNHA, to ONS 18, 
23.  Euro-QoL (EQ5D), Short Form-36 Questionnaires (SF36), Beck Depression Inventory 
(BDI-II), Hospital Anxiety (HAD-A) and Depression (HAD-D) scores were used to monitor 
quality of life and affect pre-and post-implant. 
Data was collected prospectively from 2007 until 2015 and entered onto a clinical database 
(Microsoft Excel, Microsoft Corporation, Redmond, WA, USA). 
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Statistics 
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. 
Int.).  A last observation carried forward technique was used in the case of missing data.  
Descriptive statistics were summarized as appropriate.  Data is presented as mean ± standard 
deviation or range where appropriate.  Paired and independent t-tests were used to compare 
treatment effect.  All statistical tests were two-sided with a significance level of 95%.   
 
RESULTS 
Patient demographics 
Thirty-one patients (14 male) with SUNHA were implanted between August 2007 and 
December 2013.  Provisional data from some of these patients had been previously included 
in a publication from 2014 23.  Patient demographics and baseline headache characteristics are 
shown in Table 1.  Mean age at implant was 48.9 years (range 20-74).  Seventy-seven percent 
were chronic from onset with mean chronic phase duration of 6.3 years (range 2-21 years).  
Patients had tried a mean of 7.8 preventative medications prior to ONS (range 5-11) 
summarized in Supplementary Table 1.   
Sixteen patients (51.6%) reported other headache phenotypes in addition to SUNHA: nine 
with chronic migraine, three with both chronic migraine and chronic cluster headache, two 
with hemicrania continua, one with chronic migraine and hemicrania continua, and one with 
chronic cluster headache (Table 1).  All kept separate diaries for each phenotype throughout 
follow-up. 
Whole cohort 
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Mean follow-up for all patients was 44.9 months (range 13-89 months).  At final follow-up, 
mean daily attack frequency had reduced by 69% (±38.2%) from 98.5 to 31.2 attacks 
(p=0.012).  Figure 1a shows the change in daily attack frequency over the follow-up period.  
A 50% or more reduction in daily attack frequency was observed in 77% (n=24) of patients. 
Twelve patients were pain free at final-follow up with a mean complete remission time of 
36.5 months (10-78).  Significant improvements were also seen in attack severity (5.5 points 
on verbal response scale [VRS]; p<0.001) and attack duration (64%; p=0.001) (Table 2).  At 
final follow-up, reductions in both MIDAS (40.6 points; p=0.053) and HIT-6 (4.7 point; 
p=0.017) were observed although only HIT-6 reduction was significant.  Affect scores 
showed a significant reduction in HAD-D but non-significant reductions in HAD-A and BDI-
II.  The SF36-P, SF36-M and EQ-5D all showed non-significant improvement but EQ-VAS 
showed significant improvement of 13.1 points (p=0.028) (Table 3).  Mean patient estimated 
improvement across all patients was 72% (±34.0) 
Short lasting unilateral neuralgiform headache attacks alone 
In the 15 patients with SUNHA alone, the mean follow-up was 44.2 months (range 13-81).  A 50% 
reduction in daily attack frequency was seen in 67% (n=10) at final follow-up.  Mean daily attack 
frequency reduced by 61.9% (±43.1) from152.3 to 57.5 (p=0.025).  Figure 1b shows the reduction 
in daily attack frequency over the follow-up period in this cohort.  Reductions were also seen in 
attack intensity (5.0 points on VRS; p=0.001) and attack duration (68%; p=0.011).  Significant 
improvements were seen in MIDAS (71.4 points, p=0.023) but not in HIT-6.  Affect scores showed 
significant improvements in HAD-A, HAD-D and BDI-II (Table 3) but no significant changes were 
seen in any of the other quality of life scores.  Mean patient estimated improvement was 70% 
(±38.4). 
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Multiple phenotypes including SUNHA 
In the 16 patients with multiple headache phenotypes, the mean follow-up was 45.6 (range 15-89).  
A 50% reduction in daily attack frequency was seen in 88% (n=14) at final follow-up.  Mean daily 
attack frequency reduced from 55.3 to 9.8, a change of 75% (±32.9; p=0.001).  At three-months post 
implant there was a significant difference in the reduction in attack frequency between those with 
and without multiple phenotypes (figure 1b and Table 3), at all other time points, response was 
comparable in both cohorts.  Significant changes were observed in attack severity (4.4 points on 
VRS; p=0.002) and attack duration (57%; p=0.003).  Although reductions were seen in MIDAS 
(11.5 points) and HIT-6 (4.0 points) only that in HIT-6 was significant (p=0.032).  No significant 
changes were seen in any of the affect or quality of life scores (Table 4).  Mean patient estimated 
improvement was 75% (±30.3). 
In those whose SUNHA responded to ONS, 6/11 chronic migraines, 1/3 chronic cluster 
headaches and 2/3 hemicrania continua also showed improvement (defined as a more than 
50% reduction in daily attack frequency for CCH and a more than 30% reduction in 
moderate-to-severe headache days for chronic migraine and hemicranias continua).  In those 
SUNHA non-responders, 1/2 of the co-existent chronic migraines responded to ONS. 
 
Concomitant drug use 
Twenty-five patients were taking preventative medication at time of implant (mean two 
drugs).  At follow-up six patients previously on preventative drugs had stopped all medication 
and ten had reduced the dose or number of drugs taken from baseline.  In responders to ONS, 
18/24 had medications started during follow-up, however, in only three cases was this 
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medication for SUNHA and in one patient medication for SUNHA was started after the ONS 
removed. 
Time to effect and recurrence of attacks 
The mean time of all patients to reach a 50% improvement was 5.7 months (range 1-19.0).  In 
responders this time was 5.3 months (range 1-12.0).  A significant difference was seen in daily 
attack frequency between baseline and three months in responders (85.3 attacks; p=0.031) but no 
such change was observed between month three and any other time point. 
Twelve patients had their ONS turned off for a period of time (median 8months, range 2-60 months) 
– 8 due to battery depletion, two due to lack of efficacy, one due to explantation and one due to 
technical reasons.  In ten of these, SUNHA attacks worsened with ONS off within a mean time of 
1.2 months (range 1-3). 
 
Stimulation settings 
All patients were encouraged to use continuous stimulation.  A range of settings was used to 
achieve the widest area of occipital paresthesia possible.  As a group, the range for amplitude 
was 0.20-4.65 volts (mean 1.4 volt), pulse width 294-480s (mean 441.5s) and frequency 
30-170 Hz (mean 78.3Hz). 
 
Adverse events 
A total of 35 adverse events involving 20 patients were recorded (Table 5).  Events were 
recorded as “hardware related” if they involved malfunction of a device component, 
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“biological” if they involved pain or biological reactions to the device and “stimulation-
associated” if they were related to level of stimulation.  No lead migration or electrode 
erosion was recorded in the group.  One patient (3%) suffered a minor wound infection 
requiring medical management.  Only one patient elected to have the device removed due to 
lack of efficacy after two-years.   
A total of 11 events required surgical intervention, the majority being revisions of the ONS 
system to rechargeable batteries.   
 
 
DISCUSSION AND CONCLUSIONS 
This cohort is the largest reported for ONS in intractable chronic SUNHA.  In line with 
previous open-label series of chronic cluster headache and the single series of SUNHA 
patients, we suggest that ONS may be a beneficial treatment with sustained effects for 
refractory patients 18-23.  Our series of 31 complex patients reported a significant reduction in 
daily attack frequency of 69% with 12 patients (39%) recording complete pain freedom at 
follow-up.  Overall, 77% of patients had a more than 50% reduction in daily attack frequency 
with ONS.   Significant improvements were seen in the headache-specific disability score 
HIT-6 and quality of life component EQ-VAS but not in other quality of life measures or 
MIDAS. 
Occipital nerve stimulation was first used for presumed occipital neuralgia but has since been 
used for intractable chronic migraine and chronic trigeminal autonomic cephalalgias28, 29.  
Controlled trials in chronic migraine have shown limited and conflicting evidence of efficacy 
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15-17.  Although controlled trials of ONS in trigeminal autonomic cephalalgias have not been 
completed, reviews of the open label series of chronic cluster headache report a clinical 
response in 67% of patients 29.  In the single published series of ONS for refractory SUNHA a 
cohort of nine patients was reported using headache load as primary outcome 23.  In that small 
series, 89% of patients recorded a headache load reduction of at least 50% at a median of 38 
months.  
Clinically and statistically important reductions in HIT-6, HAD-D and EQ5D-VAS scores 
were seen following ONS but no significant improvements were seen in other quality of life 
measures or migraine specific scores.   Reasons for this may include sample size, long 
duration of chronic pain (7 years), co-existent headache disorders and the usefulness of 
generic scales in measuring quality of life in headache patients.  The cohort continued to 
suffer a mean total of nearly 90 minutes of pain a-day, which, although a significant reduction 
from the pre-ONS value of 9.5 hours is still a considerable burden.  In those with multiple 
headache types not all other headaches improved.  The impact of continued disabling chronic 
headaches in this sub-population may negatively influence quality of life at follow-up and this 
is supported by a more favorable quality of life profile in those with SUNHA alone than in 
multiple phenotype patients (Table 3).  
In keeping with previous ONS series for other headache conditions our cohort reported an 
average delay of six months before reporting a clinical response and a return of attacks after 
an average of one month when stimulation was stopped 16, 18-20, 22, 23, 29.  The delay and 
reversibility of effect reflects the slow but reversible neuroplastic response proposed to 
underlie ONS treatment. 
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The adverse event profile of ONS for headache has been a major cause of criticism regards 
the treatment.  Previous ONS series reported high rates of lead migration (7-50%), lead 
fracture (10-15%) and infection (10-24%) 15, 18-21, 30.  Our cohort has a favorable adverse event 
profile with no episodes of lead migration, fracture or erosion and only one patient (3%) 
suffering a superficial wound infection requiring medical management only.  The major need 
for surgical intervention was battery replacement and with developments in neuromodulation 
technology leading to the use of longer lasting rechargeable batteries the rates of battery 
replacement should decrease in the future.  
The major weakness of this study is the lack of placebo or blinded stimulation.  However, this 
has been an issue throughout ONS research and with such a rare syndrome as SUNHA it is 
unlikely a large randomized trial will ever be completed.  Although there is undoubtedly a 
placebo effect in headache treatment it is unlikely our findings are explained by placebo 
alone.  The intractable nature of the group, the delay to clinical response in keeping with other 
trigeminal autonomic cephalalgia cohorts, the stable long-term response and the return of 
attacks when stimulation is stopped would argue against a pure placebo response.  It has also 
been reported that the placebo response rates for ONS in migraine is low (6%, 17% and 20%) 
and there is no evidence to suggest placebo response is different in other headache conditions 
15-17.   
The patient group included a high proportion of patients (52%) with multiple chronic 
headache phenotypes.  These patients had all been carefully phenotyped by headache 
specialists and patients were able to differentiate the different types recorded them in separate 
diaries to allow outcomes to be compared.  Although this percentage may seem excessive, 
other SUNHA cohorts have also described similar patterns2, 31.  It is speculated that those with 
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multiple headaches fare worse with treatment, however, our data, all be it limited, does not 
support this. Occipital nerve stimulation has been used to treat a number of headache 
conditions and we view it as a potentially useful treatment to those with multiple headache 
types as a single treatment modality can improve multiple conditions.  More work is needed 
on the outcomes of such complex patients to all treatments not just ONS, but our data 
suggests that they should not be deprived of ONS on the assumption that complex patients do 
not respond well. 
Strengths of the study include the sample size, prolonged follow-up, prospective collection of 
data and the clinical relevance of the data.  The cohorts were not selected by vigorous study 
inclusion criteria but were patients in a specialist center implanted due to clinical need when 
ONS was only available as a last-line treatment option.  The cohort will be similar to patients 
in other units conducting implants for headache conditions and so our findings should be 
widely and clinically applicable.  
Microvascular decompression and deep brain stimulation have also been reported in open-
label series to have efficacy in SUNHA disorders of around 75%, similar to the response rate 
in this ONS series 12, 29, 32-34.  The surgical experience of the team, the invasiveness of surgery, 
the associated risks, the need for implanted hardware and cost of treatment will all influence 
treatment choice.  Bearing these factors in mind, our current pathway is that patients with 
intractable SUNHA first undergo microvascular decompression (if there is evidence of 
trigeminal neurovascular contact on neuroimaging), and ONS be reserved for those with no 
neurovascular compromise or who fail to respond to microvascular decompression.  This 
order is based on our own clinical experience, technical expertise and treatment availability. 
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Our series suggests that ONS may provide a significant and sustained reduction in attack 
frequency in intractable short-lasting unilateral neuralgiform headache attacks even after four 
years follow-up.  Adverse event rates are low when implants are conducted in specialist 
centers. However, given the invasiveness and cost of treatment, ONS should be reserved for 
those who fail all other appropriate treatment options. 
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Clinical implications 
 Short lasting unilateral neuralgiform headache disorders are intensely painful and 
highly disabling. A significant minority of these patients are intractable to medical 
treatments 
 Occipital nerve stimulation (ONS) is associated with sustained reduction in daily 
attack frequency, severity and duration over a 4-year period in some patients with 
intractable short lasting unilateral neuralgiform headache disorders 
 When undertaken by highly specialised centres, the complication rates associated with 
ONS implantation are relatively low 
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